Fluzoparib
- Generic Name
- Fluzoparib
- Drug Type
- Small Molecule
- Chemical Formula
- C22H16F4N6O2
- CAS Number
- 1358715-18-0
- Unique Ingredient Identifier
- TWF0ML1CK8
- Background
Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).
- Indication
⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。
The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT03182673
- Locations
- 🇨🇳
The Cancer Center,Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
- Conditions
- Ovarian CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 98
- Registration Number
- NCT03075462
- Locations
- 🇨🇳
Beijing Cancer Hosptial, Beijing, Beijing, China
Food-Effect and Metabolism Study in Healthy Subjects
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03062982
- Locations
- 🇨🇳
the First Hosital of Jilin University, Changchun, Jilin, China
A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients
- Conditions
- Recurrent and Metastatic Gastric Cancer
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03026881
- Locations
- 🇨🇳
The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing, China
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Atridia Pty Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02759666
- Locations
- 🇦🇺
Linear, Melbourne, Australia
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺Border Medical Oncology, Albury, New South Wales, Australia
A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT02575651
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳No.307 Hospital, Academy of Military Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.